MARKET

ACRS

ACRS

Aclaris Therapeutics Inc
NASDAQ
2.330
+0.130
+5.91%
After Hours: 2.330 0 0.00% 17:08 02/14 EST
OPEN
2.180
PREV CLOSE
2.200
HIGH
2.350
LOW
2.170
VOLUME
473.67K
TURNOVER
--
52 WEEK HIGH
5.17
52 WEEK LOW
0.9515
MARKET CAP
249.35M
P/E (TTM)
-4.4825
1D
5D
1M
3M
1Y
5Y
1D
Aclaris Therapeutics announces publication describing properties of ATI-2138
TipRanks · 3d ago
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
Barchart · 3d ago
Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule
Seeking Alpha · 4d ago
Weekly Report: what happened at ACRS last week (0203-0207)?
Weekly Report · 5d ago
Weekly Report: what happened at ACRS last week (0127-0131)?
Weekly Report · 02/03 09:11
ACLARIS THERAPEUTICS ANNOUNCES FORMATION OF NEW SCIENTIFIC ADVISORY BOARD
Reuters · 01/30 21:01
Weekly Report: what happened at ACRS last week (0120-0124)?
Weekly Report · 01/27 09:12
Weekly Report: what happened at ACRS last week (0113-0117)?
Weekly Report · 01/20 09:11
More
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.

Webull offers Aclaris Therapeutics Inc stock information, including NASDAQ: ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.